Lite Strategy (LITS) Share-based Compensation (2010 - 2026)
Lite Strategy (LITS) posted quarterly Share-based Compensation of $270000.0 for Q1 2026, up 1587.5% year-over-year from $16000.0 in Q1 2025, and up 101.72% quarter-over-quarter from -$15.7 million in Q4 2025.
Lite Strategy (LITS) Share-based Compensation (2010 - 2026) Analysis & Trends
Lite Strategy's Share-based Compensation history runs 17 years deep, the most recent figure standing at $270000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1587.5% year-over-year to $270000.0; the TTM figure through Mar 2026 stood at $866000.0 (down 8.46% YoY), while the FY2025 annual figure was -$144000.0, down 106.32% from the prior year.
- Share-based Compensation for Q1 2026 stood at $270000.0, up from -$15.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $16.2 million in Q3 2025, with the low at -$15.7 million in Q4 2025.
- The 5-year median for Share-based Compensation is $397000.0 (2024), against an average of $781000.0.
- Peak annual rise in Share-based Compensation reached 12111.11% in 2025, while the deepest fall reached 15797.0% in 2025.
- Lite Strategy's Share-based Compensation stood at $813000.0 in 2022, then advanced by 4.55% to $850000.0 in 2023, then plunged by 88.24% to $100000.0 in 2024, then sank by 15797.0% to -$15.7 million in 2025, then surged by 101.72% to $270000.0 in 2026.
- Business Quant data shows LITS's Share-based Compensation at $270000.0 in Q1 2026, -$15.7 million in Q4 2025, and $16.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Lite Strategy | 33.69 Mn | 26.14 Mn | - | 270,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 270,000.00 |
| Mar 31, 2026 | 270,000.00 |
| Dec 31, 2025 | -15.70 Mn |
| Dec 31, 2025 | -15.70 Mn |
| Sep 30, 2025 | 16.22 Mn |
| Sep 30, 2025 | 16.22 Mn |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | -135,000.00 |
| Sep 30, 2024 | -135,000.00 |
| Jun 30, 2024 | 397,000.00 |
| Jun 30, 2024 | 397,000.00 |
| Mar 31, 2024 | 668,000.00 |
| Mar 31, 2024 | 668,000.00 |
| Dec 31, 2023 | 850,000.00 |
| Dec 31, 2023 | 850,000.00 |